Difference between revisions of "20.109(F21):M2D5"

From Course Wiki
Jump to: navigation, search
(Introduction)
(Protocols)
Line 11: Line 11:
  
  
===Part 2: Prepare samples for DSF assay===
+
A. Protein biotinylation for immobilization on sensor probe. The protein needs to be biotinylated to facilitate immobilization to the Streptavidin BLI probe. A detailed protocol for how this is done is available here. For these experiments, you will be provided with a biotinylated protein stock that is at 0.5 µM in 1x PBS, pH 7.4, ## mM TCEP (disulfide reducing agent).
As in the previous laboratory session, you will prepare master mixes for the conditions you will test. Because the master mixes for the DSF assay are more complicated, the below chart will assist you in completing the required calculations for each reaction. You will eventually make master mixes for each reaction, with enough volume to measure each in triplicate.
+
  
<center>
+
B. Assay plate setup. Two teams will share an assay plate and run samples together on the Octet BLI instrument. Five dilutions of the test compound will be evaluated.
{| border="1"
+
a. Each team is responsible for preparing the set of samples described in the <plate map> for that team. You will prepare samples in Eppendorf tubes, and transfer them to the specified well positions on the shared 96-well assay plate.
! Reagent (stock concentration)
+
b. Arrange Eppendorf tubes in a row in a rack and label (left to right) as outlined below:
! Final concentration of stock reagent in reaction
+
i. B = Buffer (1x PBS, pH 7.4 + 1mM TCEP)
! Volume of stock reagent in reaction
+
ii. L = Protein “loading” solution
|-
+
iii. N = Neutralization (biocytin) solution
| FKBP12 (191.6 &mu;g/mL)
+
iv. S1 = 2.5 µM test compound (Sample 1)
|1 &mu;g/30 &mu;L reaction
+
v. S2 = 5 µM test compound (Sample 2)
|
+
vi. S3 = 10 µM test compound (Sample 3)
|-
+
vii. S4 = 20 µM test compound (Sample 4)
| DMSO (3%)
+
viii. S5 = 40 µM test compound (Sample 5)
| 0.1%
+
c. Add 500 µL of buffer, protein and biocytin solutions to the Eppendorf tubes labeled B, L and N, respectively.
|
+
d. Prepare a 10 µM working stock of test compound in tube S5:
|-
+
i. Add 1 mL of 1x PBS, pH 7.4 to tube S5.
| rapamycin (150 &mu;M)
+
ii. Add 4 µL of 10 mM compound stock to tube S5.
| 5 &mu;M
+
iii. Vortex to mix thoroughly.
|
+
e. Prepare serial 2-fold dilutions of test compound in Tubes S1 – S4 as follows:
|-
+
i. Add 500 µL of 1x PBS, pH 7.4 to each of tubes S1 – S4.
| ligand, [low] (90 &mu;M)
+
ii. Tube S4: Add 500 µL of solution from Tube S5 to Tube S4, and vortex thoroughly to mix.
| 3 &mu;M
+
iii. Tube S3: Add 500 µL of solution from Tube S4 to Tube S3, and vortex thoroughly to mix.
|
+
iv. Tube S2: Add 500 µL of solution from Tube S3 to Tube S2, and vortex thoroughly to mix.
|-
+
v. Tube S1: Add 500 µL of solution from Tube S2 to Tube S1, and vortex thoroughly to mix.
| ligand, [high] (900 &mu;M)
+
f. Transfer 200 µL of each solution from Eppendorf tubes B, L, N, S1-S5 to the wells assigned to your team’s assay plate according to the plate map.
| 30 &mu;M
+
NOTE. In Column 2, you will add solution L (protein loading solution) to the top row. However, in the row below, you will add solution B (buffer). This design allows you to have a “reference” probe so you can observe how the test compound interacts with the probe, and subtract out any contribution this makes to the signal observed from the protein-loaded probe.
|
+
g. Cover the plate until it is your turn to analyze it on the Octet instrument in the Biophysical Instrumentation Facility (BIF) located in 68-470.
|-
+
| dye (30X)
+
| 1X
+
|
+
|-
+
| PBS (1X)
+
| add for a total of 30 &mu;L reaction
+
| dependent upon master mix
+
|}
+
</center>
+
  
#Perform the necessary calculations to complete the above chart for a total reaction volume of 30 &mu;L.
+
A. Running samples on Octet BLI instrument. As you’ve seen in the video, the Octet automates the introduction of multiple probes into samples, and these can be moved in parallel (to the left or right) to achieve the sequence of events needed for performing quantitative binding and dissociation assays. The following pre-set sequence will be used in your assays.
#*Confirm your values with the teaching faculty before proceeding.
+
a. Probes immersed in Column 1 (Buffer) to begin before moving to Column 2. In Column 2, protein “Loading” onto the probes will occur in odd-numbered rows, while no protein will be loaded onto the reference probes in even-numbered rows.
#Each team will setup triplicate reactions for 7 different conditions:
+
i. You should observe an increase in binding signal as protein binding to the probe occurs, while signal from the probe immersed in buffer remains flat.
#*Condition 1: no protein AND DMSO (internal control)
+
b. Probes moved back to Column 1 (“Wash” step). [Note: Biotin binds streptavidin with very high affinity, and no appreciable dissociation of the protein will be observed during this step].
#*Condition 2: FKBP12 AND DMSO (internal control)
+
c. Probes moved to Column 3 containing biocytin to block all unoccupied biotin binding sites on the protein and reference probes (“Neutralization” step). This should eliminate additional signal (background) due to test compound binding to unoccupied biotin binding sites on streptavidin.
#*Condition 3: FKBP12 AND rapamycin (5 &mu;M)
+
d. Probes moved back to Column 1 (“Wash” step).
#*Condition 4: FKBP12 AND ligand #1, (3 &mu;M)
+
e. Probes moved to Column 4 (“Association” step for the lowest test compound concentration, S1).
#*Condition 5: FKBP12 AND ligand #1, (30 &mu;M)
+
i. Data collected on the protein-loaded probe reflects compound “associating” with the protein to form a protein-small molecule complex.
#*Condition 6: FKBP12 AND ligand #2, (3 &mu;M)
+
ii. Ideally, little association of compound to the probe without protein should occur. However, as the test compound concentration is increased (i.e., from S1-S5), increased compound binding to the naked probe may occur. However, this should be lower in magnitude than what is observed for the protein-loaded probe.
#*Condition 7: FKBP12 AND ligand #2, (30 &mu;M)
+
f. Probes moved to Column 1 (“Dissociation” step).
#Generate a chart, or list, that details what reagents will be in each master mix for Conditions #1 - #7 listed above.
+
i. In this step, the small molecule unbinds from the protein complex on the probe, and gets (infinitely) diluted in the bulk buffer. The signal should exponentially decay.
#*All reactions will contain dye.
+
g. Steps (e) and (f) above are repeated for Columns 5-8 to obtain a series of association and dissociation data at progressively increasing concentrations of test compound.
#*Only reactions without rapamycin or ligand will contain DMSO.  
+
#*Include the volume of each reagent (for a final volume of 3.25 the reaction volume, which is 30 &mu;L) as each condition will be tested in triplicate.
+
#*Again, confirm your values with the teaching faculty before proceeding.
+
#Obtain the appropriate aliquots from the front laboratory bench.
+
#Use the values calculated in Step #3 to prepare your master mixes in well-labeled 1.5 mL centrifuge tubes on ice.
+
#*You will add all reagents '''except''' FKBP12 protein, as the teaching faculty will add the protein to the samples immediately prior to measuring the fluorescence signal.
+
#When you have prepared your master mixes, take them to the front laboratory bench.
+
#*Be sure that all tubes are clearly labeled!
+
 
+
 
+
===Part 3: Review journal article===
+
Critically a and discuss the following journal article with your laboratory partner:
+
 
+
Amberg-Johnson ''et al.'' "[[Media:Fa20 M2D5 paper discussion.pdf |Small molecule inhibition of apicomplexan FtsH1 disrupts plastid biogenesis in human pathogens.]]" ''eLife''. (2017) 6:e29865.
+
 
+
The initial experiment presented by Amberg-Johnson ''et. al.'' shows the effect of actinonin on apicoplast biogenesis.  The apicoplast is an essential plastid organ that is a key target for drug development in research focused on malaria treatment. Actinonin was identified in large-scale screen of compounds known to inhibit growth of parasite. The subsequent experiments completed in this research served to uncover the mechanism-of-action of actinonin is it pertains to disruption of the apicoplast.
+
 
+
In the context of your research, this article focuses on the next step experiments that can be performed after a drug candidate is discovered from a screen.  Though you can use this article as guidance as you consider the experiments that could follow your screen, remember that the specific next step experiments should be related to the protein target and drug candidate(s) identified in your project.  For this exercise, the focus in on how the data are organized and presented.
+
 
+
<font color =  #4a9152 >'''In your laboratory notebook,'''</font color> complete the following with your partner:
+
*Why is the apicoplast a promising target for anti-malarial drug development?
+
*Why have attempts at developing broadly effective drugs that target the apicoplast been unsuccessful?
+
*Why is the approach used by the researchers in this article more promising?
+
*List the figures that are included in the article. For each figure:
+
**What is the main conclusion / finding in each figure?
+
**Which panel best supports the main conclusion / finding?  Is more than one panel needed to fully support the main conclusion?
+
**Are you convinced by the data?  Do you agree with the main conclusion?
+
*Are the figures organized in a coherent story?
+
**Write transition statement that connect each figure to the next.  A transition statement should very briefly summarize the findings of a figure and state what those findings motivated the research to do next (ie what is the next experiment?).
+
  
 
==Reagent list==
 
==Reagent list==

Revision as of 04:16, 30 October 2021

20.109(F21): Laboratory Fundamentals of Biological Engineering
Drawing provided by Marissa A., 20.109 student in Sp21 term.  Schematic generated using BioRender.

Fall 2021 schedule        FYI        Assignments        Homework        Class data        Communication        Accessibility

       Module 1: Genomic instability                          Module 2: Drug discovery       


Introduction

describe DSF...

Protocols

A. Protein biotinylation for immobilization on sensor probe. The protein needs to be biotinylated to facilitate immobilization to the Streptavidin BLI probe. A detailed protocol for how this is done is available here. For these experiments, you will be provided with a biotinylated protein stock that is at 0.5 µM in 1x PBS, pH 7.4, ## mM TCEP (disulfide reducing agent).

B. Assay plate setup. Two teams will share an assay plate and run samples together on the Octet BLI instrument. Five dilutions of the test compound will be evaluated. a. Each team is responsible for preparing the set of samples described in the <plate map> for that team. You will prepare samples in Eppendorf tubes, and transfer them to the specified well positions on the shared 96-well assay plate. b. Arrange Eppendorf tubes in a row in a rack and label (left to right) as outlined below: i. B = Buffer (1x PBS, pH 7.4 + 1mM TCEP) ii. L = Protein “loading” solution iii. N = Neutralization (biocytin) solution iv. S1 = 2.5 µM test compound (Sample 1) v. S2 = 5 µM test compound (Sample 2) vi. S3 = 10 µM test compound (Sample 3) vii. S4 = 20 µM test compound (Sample 4) viii. S5 = 40 µM test compound (Sample 5) c. Add 500 µL of buffer, protein and biocytin solutions to the Eppendorf tubes labeled B, L and N, respectively. d. Prepare a 10 µM working stock of test compound in tube S5: i. Add 1 mL of 1x PBS, pH 7.4 to tube S5. ii. Add 4 µL of 10 mM compound stock to tube S5. iii. Vortex to mix thoroughly. e. Prepare serial 2-fold dilutions of test compound in Tubes S1 – S4 as follows: i. Add 500 µL of 1x PBS, pH 7.4 to each of tubes S1 – S4. ii. Tube S4: Add 500 µL of solution from Tube S5 to Tube S4, and vortex thoroughly to mix. iii. Tube S3: Add 500 µL of solution from Tube S4 to Tube S3, and vortex thoroughly to mix. iv. Tube S2: Add 500 µL of solution from Tube S3 to Tube S2, and vortex thoroughly to mix. v. Tube S1: Add 500 µL of solution from Tube S2 to Tube S1, and vortex thoroughly to mix. f. Transfer 200 µL of each solution from Eppendorf tubes B, L, N, S1-S5 to the wells assigned to your team’s assay plate according to the plate map. NOTE. In Column 2, you will add solution L (protein loading solution) to the top row. However, in the row below, you will add solution B (buffer). This design allows you to have a “reference” probe so you can observe how the test compound interacts with the probe, and subtract out any contribution this makes to the signal observed from the protein-loaded probe. g. Cover the plate until it is your turn to analyze it on the Octet instrument in the Biophysical Instrumentation Facility (BIF) located in 68-470.

A. Running samples on Octet BLI instrument. As you’ve seen in the video, the Octet automates the introduction of multiple probes into samples, and these can be moved in parallel (to the left or right) to achieve the sequence of events needed for performing quantitative binding and dissociation assays. The following pre-set sequence will be used in your assays. a. Probes immersed in Column 1 (Buffer) to begin before moving to Column 2. In Column 2, protein “Loading” onto the probes will occur in odd-numbered rows, while no protein will be loaded onto the reference probes in even-numbered rows. i. You should observe an increase in binding signal as protein binding to the probe occurs, while signal from the probe immersed in buffer remains flat. b. Probes moved back to Column 1 (“Wash” step). [Note: Biotin binds streptavidin with very high affinity, and no appreciable dissociation of the protein will be observed during this step]. c. Probes moved to Column 3 containing biocytin to block all unoccupied biotin binding sites on the protein and reference probes (“Neutralization” step). This should eliminate additional signal (background) due to test compound binding to unoccupied biotin binding sites on streptavidin. d. Probes moved back to Column 1 (“Wash” step). e. Probes moved to Column 4 (“Association” step for the lowest test compound concentration, S1). i. Data collected on the protein-loaded probe reflects compound “associating” with the protein to form a protein-small molecule complex. ii. Ideally, little association of compound to the probe without protein should occur. However, as the test compound concentration is increased (i.e., from S1-S5), increased compound binding to the naked probe may occur. However, this should be lower in magnitude than what is observed for the protein-loaded probe. f. Probes moved to Column 1 (“Dissociation” step). i. In this step, the small molecule unbinds from the protein complex on the probe, and gets (infinitely) diluted in the bulk buffer. The signal should exponentially decay. g. Steps (e) and (f) above are repeated for Columns 5-8 to obtain a series of association and dissociation data at progressively increasing concentrations of test compound.

Reagent list

  • DSF dye (Thermo Fisher)
  • ligands (Chembridge)

Navigation links

Next day: Perform secondary assay to test putative small molecule binders

Previous day: Assess purity and concentration of purified protein